CancerRadarCancerRadar
Monoclonal antibodyPhase 3 trialInvestigational

Olaratumab

How it works

Blocks the action of platelet-derived growth factor (PDGF), which fuels cancer cell growth.

Cancer types

Prostate Cancer

Efficacy

Studies show that approximately 40% of patients achieved a PSA response, with a median radiographic progression-free survival of around 20 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.